Senores Pharmaceuticals informs about financial results

20 Jan 2026 Evaluate
Senores Pharmaceuticals has informed that the Board of Directors of the Company at their Meeting held today, Tuesday, January 20, 2026 has approved the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025, together with the Limited Review Report thereon, issued by Pankaj R. Shah and Associates, Chartered Accountants. The Un-audited Standalone and Consolidated financial results along with the reports of the auditors of the Company are enclosed herewith as Annexure-A. Media Release in relation to the Un-audited Standalone and Consolidated financial results of the Company for the quarter and nine months ended December 31, 2025 is enclosed as Annexure -B. The meeting of Board of Directors of the Company commenced at 11:30 AM (IST) and concluded at 01:20 PM (IST). This intimation and aforesaid information are also being uploaded on the Company’s website at www.senorespharma.com.

The above information is a part of company’s filings submitted to BSE.

Senores Pharmaceutic Share Price

837.15 2.35 (0.28%)
22-Jan-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1374.60
Zydus Lifesciences 883.85
Lupin 2165.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×